CLINICAL_TRIALS
trial_result
· 2021-06-23
Clinical Trial Update: Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation [Phase 2]
Summary
Phase 2 trial updating the combination of fulvestrant and anlotinib in HR+/HER2- metastatic breast cancer with FGFR mutation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN